Advertisement
Advertisement
EBS
Emergent Biosolutions, Inc.
6.79
USDSponsored
+0.02
+0.30%
Sep 25, 15:59 UTC -4
Closed
After-Market
6.79
0.00
+0.07%
EBS Earnings Reports
Positive Surprise Ratio
EBS beat 23 of 43 last estimates.
53%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$124.43M
/-$0.39
Implied change from Q2 26 (Revenue/ EPS)
-46.89%
/-165.00%
Implied change from Q3 25 (Revenue/ EPS)
-46.16%
/-136.79%
Emergent Biosolutions, Inc. earnings per share and revenue
On Aug 05, 2026, EBS reported earnings of 0.60 USD per share (EPS) for Q2 26, beating the estimate of 0.11 USD, resulting in a 440.05% surprise. Revenue reached 234.30 million, compared to an expected 179.28 million, with a 30.69% difference. The market reacted with a -29.58% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.39 USD, with revenue projected to reach 124.43 million USD, implying an decrease of -165.00% EPS, and decrease of -46.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Emergent Biosolutions, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Emergent Biosolutions, Inc. reported EPS of $0.60, beating estimates by 440.05%, and revenue of $234.30M, 30.69% above expectations.
How did the market react to Emergent Biosolutions, Inc.'s Q2 2026 earnings?
The stock price moved down -29.58%, changed from $7.54 before the earnings release to $5.31 the day after.
When is Emergent Biosolutions, Inc. expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Emergent Biosolutions, Inc.'s next earnings report?
Based on --
analysts, Emergent Biosolutions, Inc. is expected to report EPS of -$0.39 and revenue of $124.43M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.